1. You are here:
  2. BioIndustry Association
  3. Member profile: Scripta Therapeutics

Scripta Therapeutics

Industrial Biotech

  • Funding stage: Seed
  • Technology type: Tech Bio
  • Oxford
Email
[email protected]
Website
https://www.scriptatherapeutics.com
Membership category
Emerging Y1

Magdalen Centre, 1 Robert Robinson Avenue, Oxford, OX4 4GA, United Kingdom

Scripta Therapeutics at a glance

Scripta Therapeutics is a Oxford-based techbio company takes a biology-first approach to discover disease-modifying drugs that modulate transcription factor activity and reprogram biology

About Scripta Therapeutics

Scripta aims to discover and develop disease modifying therapeutics for neurodegenerative disorders. The company is following a unique strategy, based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of disease. Therapeutics that modulate these maps to restore the healthy cell state can be efficiently identified by a data-rich, lab-in-the-loop combination of experimental biology and cutting-edge AI and informatics.

Therapeutic area(s)

  • Neurology

Articles Scripta Therapeutics has contributed to

Scripta_logo_centre_blackbg_224x192.png
12 November 2025

Flipping the script: Scripta Therapeutics raises $12 million to find disease-modifying drugs that alter transcription factor activity

Oxford-based techbio startup Scripta Therapeutics emerges from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science Enterprises (OSE) and Apollo Health Ventures, with further investment from AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation.

Member news